Why Unlimited Capital Can't Speed Up Clinical Trials

Even with virtually unlimited funding, clinical trials remain mired in delays. The bottleneck, experts say, isn't money but operational inefficiencies at research sites. Private equity firms are now deploying advanced analytics and artificial intelligence to streamline these fragmented systems, aiming to capitalize on the inefficiencies of current trial infrastructure. This strategy marks a significant shift in how the industry approaches data management and patient connectivity.